Fentanyl buccal tablet: Rapid relief from breakthrough pain

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 17, 2007, Pages 3043-3051

  Taylor, Donald R ^a  

^a Comprehensive Pain Care ^*  (United States)

Author keywords

Analgesia; Breakthrough pain; Effervescent; Fentanyl buccal tablet; Opioid agonist

Indexed keywords

FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; KETAMINE; MORPHINE; NARCOTIC ANALGESIC AGENT; PLACEBO;

ANALGESIA; ANALGESIC ACTIVITY; APPLICATION SITE REACTION; ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; BREAKTHROUGH PAIN; CANCER PAIN; CHEEK MUCOSA; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG PENETRATION; DRUG POTENCY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EFFERVESCENT TABLET; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; LOW BACK PAIN; NAUSEA; NEUROPATHIC PAIN; OXYGEN THERAPY; PAIN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RESPIRATION DEPRESSION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH MOTILITY; TABLET FORMULATION; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, BUCCAL; ANALGESICS, OPIOID; ANIMALS; FENTANYL; HUMANS; PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; TABLETS; TREATMENT OUTCOME;

EID: 37349125554     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.17.3043     Document Type: Article

References (30)

1. CARACENI A, MARTINI C, ZECCA E et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat. Med. (2004) 18:177-183.
2. PORTENOY RK, BENNETT DS, RAUCK R et al.: Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J. Pain (2006) 7:583-591.
3. BENNETT D, BURTON A, FISHMAN S et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1. Assessment. Pharm. Ther. (2005) 30:296-301.
4. PORTENOY RK, HAGEN NA: Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 41:273-281.
5. PORTENOY RK, PAYNE D, JACOBSEN P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain (1999) 81:129-134.
6. MERCADANTE S, MADDALONI S, ROCCELLA S, SALVAGGIO L: Predictive factors in advanced cancer pain treated only by analgesics. Pain (1992) 50:151-155.
7. MERCADANTE S, ARMATA M, SALVAGGIO L: Pain characteristics of advanced lung cancer patients referred to a palliative care service. Pain (1994) 59:141-145.
8. FORTNER BV, OKON TA, PORTENOY RK: A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J. Pain (2002) 3:38-44.
9. FORTNER BV, DEMARCO G, IRVING G et al.: Description and predictors of direct and indirect costs of pain reported by cancer patients. J. Pain Symptom Manage. (2003) 25:9-18.
10. BENNETT D, BURTON AW, FISHMAN S et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. Pharm. Ther. (2005) 30:354-361.
11. FINE PG, MARCUS M, DE BOER AJ, VAN DER OORD B: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain (1991) 45:149-153.
12. FARRAR JT, CLEARY J, RAUCK R, BUSCH M, NORDBROCK E: Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J. Natl. Cancer Inst. (1998) 90:611-616.
13. MYSTAKIDOU K, KATSOUDA E, PARPA E, TSIATAS ML, VLAHOS L: Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am. J. Hosp. Palliat. Care (2005) 22:228-232.
14. GHEE S, CUNNINGHAM J, ROME J, REID K: Dental disease and the use of oral transmucosal fentanyl - a case report. 23rd Annual Meeting of the American Academy of Pain Medicine. New Orleans, LA, USA (7-10 February 2007).
15. STANLEY TH: Fentanyl. J. Pain Symptom Manage. (2005) 29(5 Suppl.):S67-S71.
16. DURFEE S, MESSINA J, KHANKARI R: Fentanyl effervescent buccal tablets. Am. J. Drug Deliv. (2006) 4:1-5.
17. STREISAND JB, ZHANG J, NIU S, MCJAMES S, NATTE R, PACE NL: Buccal absorption of fentanyl is pH-dependent in dogs. Anesthesiology (1995) 82:759-764.
18. DARWISH M, KIRBY M, ROBERTSON P Jr, HELLRIEGEL E, JIANG JG: Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J. Clin. Pharmacol. (2007) 47:56-63.
19. MATHER LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet. (1983) 8:422-446.
20. HILL HF, CHAPMAN CR, SAEGER LS et al.: Steady-state infusions of opioids in human. II. Concentration-effect relationships and therapeutic margins. Pain (1990) 43:69-79.
21. DARWISH M, KIRBY M, JIANG JG: Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin. Pharmacother. (2007) 8:2011-2016.
22. DARWISH M, KIRBY M, ROBERTSON P, TRACEWELL W, JIANG JG: Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol. (2007) 47:343-350.
23. DARWISH M, KIRBY M, ROBERTSON P, TRACEWELL W, JIANG JG: Absorption of fentanyl from fentanyl buccal tablet (FBT) in cancer patients with or without oral mucositis - a pilot study. Clin. Drug Investig. (2007) 27:605-611.
24. PORTENOY RK, TAYLOR D, MESSINA J, TREMMEL L: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain (2006) 22:805-811.
25. SLATKIN NE, XIE F, MESSINA J SEGAL TJ: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol. (2007) 5:327-334.
26. SIMPSON DM, MESSINA J, XIE F, HALE M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. (2007) 29:588-601.
27. PORTENOY RK, MESSINA J, XIE F, PEPPIN J: Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr. Med. Res. Opin. (2007) 23:223-233.
28. NALAMACHU S, XIE F, MESSINA J: Mood, functioning, and quality of life in opioid-tolerant patients with noncancer chronic pain and breakthrough pain: effect of fentanyl buccal tablet. J. Pain (2007) 8:S43.
29. WEBSTER LR: Fentanyl buccal tablets. Expert Opin. Investig. Drugs (2006) 15:1469-1473.
30. TAYLOR DR, MESSINA J, XIE F, WEBSTER L: Multi-study analysis of patients' preference for fentanyl buccal tablet (FBT) in the management of breakthrough pain. 26th Annual Scientific Meeting of the American Pain Society. Washington, DC, USA (2-5 May 2007).